Monte Rosa takes this week's IPO lead as a nine-figure raise pushes industry total past $9B
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Major League Baseball isn’t the only industry that’s undergoing a reckoning over “sticky stuff,” as Monte Rosa Therapeutics takes its molecular glues public Thursday ready to shake up Nasdaq.
The Boston-based biotech priced its IPO late Wednesday night and plans to start trading Thursday at a launch price of $19 per share. Monte Rosa secured $222.3 million with the offering as biotech continues its record IPO pace: now with 54 companies going public in 2021, the industry is on track to see more than 100 debuts in a calendar year for the first time ever, according to the Endpoints News tally.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters